Project Grant R43AG077737

Award Date 8/15/22
Completion Date 7/31/24
Dollars Obligated $899K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
El Dorado Hills, CA 95762, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $811,228 to B.A. Maze, Inc. to develop and test the At-Home Health Station (AHS), a technology platform designed to assist individuals with cognitive impairment and Alzheimer's disease-related dementias (CI/ADRD) in maintaining independence and health. The AHS is a modular, plug-and-play system that simplifies digital experiences for CI/ADRD users and enables caregivers to set customized...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $864,674 to Lifebio Inc., a self-certified small disadvantaged business, to develop a tablet-based platform called "LifeBioTalk." The LifeBioTalk platform is designed to provide engaging audio-visual content narrated by a human-like avatar to people with Alzheimer's disease and related dementias (ADRD). The goal is to use this simulated conversational experience to reduce challenging...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,588,040 to Wake Forest University Health Sciences to examine the use of home-based medical care (HBMC) and telemedicine among people living with Alzheimer's disease and related dementias (PLWD) in both public (Medicare fee-for-service) and private (Medicare Advantage) insurance plans. The study aims to identify national trends in HBMC and telemedicine utilization, and rigorously...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $2,245,769 aims to develop an integrated brain state monitoring system for personalized anesthesia decision support to prevent postoperative delirium in elderly and at-risk patients. The project, awarded to Pascall Systems, Inc., a for-profit medical technology company, focuses on four key objectives: Establishing technical feasibility for integrating the company's FDA-cleared wireless EEG...
This $334,788 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the impact of recent revisions to the Medicare home health payment system (Patient-Driven Groupings Model or PDGM) on access, care delivery, and outcomes for community-living Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The 2-year study, starting September 1, 2023, will leverage Medicare claims, home health assessment, and agency data to:...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), has awarded a $299,553 Project Grant to Pilltrax Systems LLC to develop an enhanced medication management service for providers caring for African American and Latino older adults at risk of Alzheimer's disease and related dementias (ADRD). The proposed solution will comprise an electronic pill dispenser that sends medication adherence notifications, an adherence assessment tool, and a provider...
This $349,333 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development and feasibility testing of a virtual reality (VR) platform called "VR-CARES" to provide social support and enrichment for in-home dementia caregivers. The key products and services to be delivered through this STTR Phase I study include: Co-developing the VR-CARES platform with input from dementia caregivers to ensure it aligns with their needs and experiences....
This $243,000 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 5-year research study to identify factors and develop an intervention for deprescribing potentially inappropriate medications among older adults with Alzheimer's disease and related dementias (ADRD) receiving home health care. The study aims to: 1) use mixed methods to determine barriers and facilitators to routine deprescribing practices in home health care for ADRD patients, and...
This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the federal Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program aims to improve long-term care (LTC) quality and safety for individuals living with dementia. With $449,999 in funding, the 3-year project starting September 2024 will implement and evaluate two decision support technology (DS tech) prototypes focused on fall prevention and staff burnout detection in LTC facilities. The...
This $1,933,556 Project Grant awarded by the National Institute on Aging (NIA) under its Aging Research program (CFDA 93.866) will support research to assess the impact of hospital-based health information technology (hospital-HIT) on healthcare quality and equity for patients with Alzheimer's disease and related dementias (ADRD). The primary awardee, the University of Maryland, College Park, will conduct a ten-year longitudinal study to evaluate how hospital-HIT systems that promote care...

PREVENTING MEDICATION MISMANAGEMENT IN PEOPLE LIVING WITH DEMENTIA THROUGH AUTOMATED MEDICATION DISPENSING WITH FACIAL RECOGNITION AND VIDEO OBSERVATION - GLOBALLY, OVER 47 MILLION INDIVIDUALS ARE LIVING WITH DEMENTIA, WITH NEW INCIDENCE OF 7.7 MILLION ANNUALLY. MEDICATION MISMANAGEMENT IS ONE OF THE MOST COMMON AND CONCERNING RISK FACTORS IN PEOPLE WITH DEMENTIA (PWD), AS IT LEADS TO UNDERTREATMENT OF DISEASE, EMERGENCY DEPARTMENT VISITS, HOSPITAL ADMISSIONS/READMISSIONS, AND SERIOUS ADVERSE EVENTS. IN THE U.S. AN ESTIMATED 3 MILLION OLDER ADULTS ARE ADMITTED TO NURSING HOMES DUE TO DRUG-RELATED ADHERENCE PROBLEMS WITH ANNUAL COST EXCEEDING $14 BILLION. THE CHALLENGE IS COMPLEX MEDICATION MANAGEMENT REQUIRES MODERATE EXECUTIVE FUNCTIONING. HOWEVER, AS COGNITIVE FUNCTION DECLINES, PWD CAN NO LONGER PERFORM SUCH INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADLS) SAFELY, EFFECTIVELY, AND INDEPENDENTLY. WHILE THE GOAL IS TO KEEP OLDER ADULTS AT HOME AS LONG AS POSSIBLE, CAREGIVERS ARE NOT AVAILABLE 24/7 & COSTS OF EXTERNAL CARE ARE OFTEN PROHIBITIVE. THE HIDO PLATFORM WILL SOLVE THESE MARKET CHALLENGES BY AUTOMATING MEDICATION ADMINISTRATION FOR PWD TO ELIMINATE MISMANAGEMENT, DECREASE CAREGIVER BURDEN, REDUCE HEALTHCARE UTILIZATION AND FACILITATE THE ABILITY FOR PWD TO AGE IN PLACE. WHILE STILL PREMARKET, HIDO IS BEING DESIGNED AND VALIDATED AS AN AUTOMATED, AI DRIVEN MEDICATION DISPENSING AND DIRECT OBSERVATION PLATFORM TO OPTIMIZE ADHERENCE. THE INNOVATIVE DEVICE INTEGRATES MEDICATION DISPENSING, DOSE ADMINISTRATION TIME, MEDICATION SYNCHRONIZATION, AND A PAIR OF FRONT-FACING VIDEO CAMERAS TO VALIDATE THE RIGHT MEDICATIONS, THE RIGHT ROUTE, RIGHT TIME, RIGHT DOSAGE TO THE RIGHT PATIENT (5R'S). THE CAMERAS RECORD EVERY DOSE USING FACIAL RECOGNITION & PROVIDE REAL-TIME MEDICATION CONSUMPTION RECORDINGS FOR MEDICAL REVIEW IF NEEDED BY MONITORING THE TIME A PATIENT INTERACTS WITH THE DEVICE. THROUGH CLOUD CONNECTIVITY, PROVIDERS & CAREGIVERS HAVE ACCESS TO VIDEO OBSERVATION LOGS, DOSE ADMINISTRATION TIME, ADHERENCE TRENDS, & LONGITUDINAL ADHERENCE THROUGH THE PLATFORM'S DASHBOARD. PATIENTS & CAREGIVERS CAN EASILY SETUP COMPLEX MEDICATION PROTOCOLS IN MINUTES USING A SMARTPHONE APP. THE DEVICE THEN ALERTS PATIENTS AND DISPENSES UP TO 7 DIFFERENT TYPES OF MEDS SIMULTANEOUSLY, WITH UP TO 40 DOSES EACH. THE FULLY COMMERCIALIZED HIDO PLATFORM WILL INTEGRATE THE FULL FEATURE SUITE ABOVE. HOWEVER, TO DEMONSTRATE FEASIBILITY, PHASE I WILL TARGET AN IN-CLINIC USABILITY STUDY, PLATFORM ENHANCEMENTS & NOVEL AI TO CONFIRM INGESTION, AND REMOTE PILOT STUDY TO DOCUMENT INDEPENDENT USABILITY & ADHERENCE IN PWD. AN EXISTING PROTOTYPE HIDO PLATFORM, WHICH ALREADY INTEGRATES FACIAL RECOGNITION AI, WILL BE LEVERAGED AS A BASE TECHNOLOGY TO INCREASE LIKELIHOOD OF PROJECT SUCCESS. FIRST, USING THE EXISTING PROTOTYPE WE WILL COMPLETE AN IN-CLINIC USABILITY STUDY TO VALIDATE USE CASES AND PRODUCT FEATURES IN THE TARGET POPULATION. THE EXISTING PLATFORM WILL THEN BE ENHANCED WITH MACHINE VISION AI TO CONFIRM MEDICATION INGESTION, AS WELL AS UPDATES TO ADDRESS CHALLENGES FOUND IN EARLY USABILITY. ONCE THE ENHANCED PLATFORM HAS BEEN TECHNICALLY VERIFIED, IT WILL BE DEPLOYED IN A REMOTE FIELD USABILITY STUDY WITH PWD AND CAREGIVERS.

Posted 8/15/22, 12:00 AM